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Abstract: Human plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor with a
metastable active conformation. The lifespan of the active form of PAI-1 is modulated via
interaction with the plasma protein, vitronectin, and various metal ions. These metal ions fall into
two categories: Type I metals, including calcium, magnesium, and manganese, stabilize PAI-1 in
the absence of vitronectin, whereas Type II metals, including cobalt, copper, and nickel, destabilize
PAI-1 in the absence of vitronectin, but stabilize PAI-1 in its presence. To provide a mechanistic
basis for understanding the unusual modulation of PAI-1 structure and activity, the binding
characteristics and conformational effects of these two types of metals were further evaluated.
Steady-state binding measurements using surface plasmon resonance indicated that both active
and latent PAI-1 exhibit a dissociation constant in the low micromolar range for binding to
immobilized nickel. Stopped-flow measurements of
approach-to-equilibrium changes in intrinsic protein fluorescence indicated that the Type I and
Type II metals bind in different modes that induce distinct conformational effects on PAI-1.
Changes in the observed rate constants with varying concentrations of metal allowed accurate
determination of binding affinities for cobalt, nickel, and copper, yielding dissociation
constants of ~40, 30, and 0.09 lM, respectively. Competition experiments that tested effects on
PAI-1 stability were consistent with these measurements of affinity and indicate that copper binds
tightly to PAI-1.
Keywords: PAI-1; serpins; metals; vitronectin
Introduction

Abbreviations: BSA, bovine serum albumin; EDTA, ethylenediaminetetraacetic acid; MOPS, 3-(N-morpholino)-propanesulfonic
acid; NTA, nitrilotriacetic acid; PAI-1, human plasminogen activator inhibitor type 1; PDB, protein data bank; serpin, serine
protease inhibitor; SP, methyl sulfopropyl; SPR, surface plasmon resonance; t1/2, half-life; tc-tPA, two-chain tissue plasminogen activator; Tris, tris(hydroxymethyl)aminomethane.
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Recent surveys of the protein data bank (PDB) show
that 40% of proteins contain metal cofactors that serve
a structural and/or functional capacity.1 They assist in
protein folding and stability or provide sites for substrate
binding and catalysis. Metals give proteins functional
flexibility because of their potential to bind to an assortment of ligands and perform quite diverse chemistries.2
Under physiological conditions, the most common metals
bound to proteins are Naþ, Kþ, Mgþ2, Caþ2, Znþ2, Mnþ2,
Niþ2, Cuþ1/þ2, Feþ2/þ3, and Coþ2/þ3.2 These metals were
selected early in protein evolution because of their
relatively high abundance in nature.3
The heavier metals are lower in abundance and
are highly regulated. Most are bound to a series of
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carrier proteins that deliver the metals to specific
organs/cell types. From there, they are passed along
to intracellular transporters via additional carrier
proteins and finally to the target. The metals are
bound during protein synthesis or once a particular
function is needed.4–6 In this way, the likelihood of
protein/metal binding in the physiological environment is determined both by the metal binding affinity of the protein and local metal bioavailability
because of the action of carriers and transporters.
Human plasminogen activator inhibitor-1 (PAI1) is a serine protease inhibitor (serpin) that spontaneously undergoes a large conformational change,
switching the protein from an active to latent form.7
At 37 C and neutral pH, the half-life (t1/2) of the
active form is 1–2 h.8–17 Binding of PAI-1 to the
plasma protein, vitronectin, extends its functional t1/
8,9,11,13,17
This is a high affinity interac2 by 50%.
tion (Kd of 0.1–1 nM) such that vitronectin is often
called a PAI-1 cofactor.18–23 These two proteins are
located primarily in plasma and the extracellular
space where they inhibit fibrinolysis or extracellular
proteolysis, control cellular adhesion and migration,
and assist in the inflammatory response.24–34 In our
previous report35, we have shown that calcium, magnesium, and manganese (referred to as Type I metals) have a modest stabilizing effect on the t1/2 of
PAI-1, whereas cobalt, copper, and nickel (referred
to as Type II metals) effect a vitronectindependent modulation of the t1/2 of PAI-1. The Type
II metals induce a substantial destabilization of PAI1, reducing t1/2 to a few minutes. However, with
vitronectin present in addition to the metals, the
half-life of PAI-1 increases up to 40-fold.
In this accompanying study, we establish binding affinities for the Type II metals and demonstrate
the differential conformational effects induced on
PAI-1 by the Type I versus II metals. This was
accomplished initially via steady-state binding
experiments using surface plasmon resonance (SPR)
and then was expanded to provide insight into the
binding mechanism using transient-state kinetic
measurements. Consistent with our previous metal
categorization,35 the Type I and II metals promote
different changes in PAI-1 intrinsic protein fluorescence upon binding, suggesting that each group of
metals binds via unique interactions that induce differing effects on PAI-1 structure. These data also
indicate that cobalt and nickel bind to PAI-1 with a
dissociation constant in the low micromolar range,
whereas copper binds with 200-fold stronger affinity. Thus, the binding of copper to PAI-1 occurs at
concentrations that are well within the range of copper bioavailability. The ability of copper to modulate
PAI-1 structure and activity represents a previously
unrecognized control on the ability of this serpin to
regulate plasminogen activation in the circulation
and tissues.
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Results
Both active and latent PAI-1 bind to
immobilized nickel
The concentrations of metals used in our previous
PAI-1 stability measurements were intentionally set
to high values35 to ensure that the effects were
measured under saturating conditions. Thus, it is
now important to evaluate binding directly to determine whether metal affinities are in a physiological
range. Because the Type II metals destabilize PAI-1
so that the active form converts to the latent form
within minutes, typical steady-state titrations to
measure metal binding are not practical. Therefore,
to probe the PAI-1/metal binding affinity, we immobilized nickel onto a nitrilotriacetic acid (NTA) chip
for SPR runs and then passed varying concentrations of active PAI-1 over the surface.
A plot of change in total response units at equilibrium versus the total concentration of active PAI1 was used to quantify binding to the nickel-NTA
chip.36 These data were best fit to a model that
included both a hyperbolic function for high-affinity
binding behavior, with an additional linear function
due to a lower affinity nonspecific metal binding.
This treatment gave the active PAI-1/nickel dissociation constant of 6.5 6 0.2 lM. Replicate experiments
with latent PAI-1 were fit directly to a single-site
binding isotherm [Fig. 1(A)], yielding the latent PAI1/nickel dissociation constant of 22 6 3 lM. Active
PAI-1 binds approximately threefold tighter than
latent PAI-1, suggesting that the shortened t1/2 for
the active form of PAI-1 with nickel present cannot
be due to preferential binding of metal to the latent
form. Instead, the perturbed half-life is more likely
due to a specific, metal-induced conformational
change in the active form of PAI-1 that favors
conversion to the latent form.
To assess whether Type I and Type II metals
bind to the same or different sites on PAI-1, a direct
test for competition for binding sites was taken
using the SPR method. In this case, varying
amounts of MgCl2 (Type I metal) were mixed with
PAI-1 before injection over a nickel (Type II metal)coated SPR chip. At high concentrations, MgCl2 is
observed to inhibit PAI-1 binding to nickel [Fig.
1(B)], indicating that magnesium can bind to the
Type II site but with very low affinity. This result
suggests that a single metal site is able to accommodate binding of Type I and Type II metals, which
have opposing effects depending on the metal bound.

Metal binding to PAI-1 can be monitored
using measurements of changes in
intrinsic fluorescence
Our previous experiments demonstrating differences
in effects of metal binding on the stability of PAI-1
indicate that binding sites, affinities, and
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fulfilled without an intact coordination chemistry
intrinsic to a protein structure. Furthermore, the
SPR method gives no information about mechanisms
of binding or effects on protein structure. Therefore,
to measure binding directly, determine affinity, evaluate structural effects, and explore differences
between Type I and II metal interactions with PAI1, a spectroscopic method was used. We compared
steady-state fluorescence emission spectra for active
and latent PAI-1 in the absence of metals and
observed a change in the intrinsic tryptophan fluorescence of the two forms of PAI-1, with latent PA-1
exhibiting a lower overall quantum yield (data now
shown). This difference in tryptophan fluorescence
between the two forms of PAI-1 allowed us to develop a stopped-flow method that relied on
approach-to-equilibrium changes in intrinsic protein
fluorescence upon rapid mixing of PAI-1 with metals.
The kinetic method allowed for evaluation of the
mechanism of metal binding and associated changes
in conformation, which cannot be revealed from
steady-state measurements.
Because typical PAI-1 preparations contain
EDTA and its removal by dialysis is problematic,37,38
it was necessary to develop a purification protocol
for PAI-1 without the addition of EDTA. As
described in the Materials and Methods section,
ChelexV resin was used to remove all metal during
the modified purification procedure. This modification also ensured no EDTA was present to interfere
with the stopped-flow binding experiments. The
half-life (t1/2) of the active conformation of human
PAI-1 has been determined on several occasions
by different groups, with results that range from
1.5 h to over a day,8–17 likely attributable in part
to varied buffer conditions for the experiments. In
our companion article,35 we measured PAI-1 stability
in Tris buffer at 37 C and pH 7.4, resulting in a t1/2
of 1–2 h. In our stopped-flow approach, we chose
20 C to extend the active lifespan of PAI-1 and readily observe multiple steps in the binding mechanism.
We also compared measurements in MOPS and Tris
buffers at pH 7.4.
The purified PAI-1 (free of chelators) exhibited
measurable changes in intrinsic fluorescence in
stopped-flow experiments in which Type I or II metals were mixed with PAI-1, providing a promising
method to quantify binding and evaluate mechanistic details. In control experiments in which PAI-1
was mixed with buffer alone, the intrinsic protein
fluorescence decreased slightly over time (data not
shown), an effect that is likely due to photobleaching. To correct for this background loss of fluorescence, it was subtracted from all experiments with
metals. The stopped-flow experiments were pursued
with the Type II transition metals that had such
dramatic effects on PAI-1 activity and stability.
Under pseudo-first-order conditions, mixing of PAI-1
R

Figure 1. Evaluation of PAI-1 binding to nickel using
surface plasmon resonance. Nickel was bound to an
NTA-coupled chip, and PAI-1 binding was measured at
equilibrium using SPR by injecting varying concentrations
and flowing the solution over the chip (see Materials and
Methods). In Panel A, the change in response units upon
binding of active (l) or latent (*) PAI-1 to immobilized
nickel was corrected for nonspecific binding, normalized,
and fit to the equation for a hyperbolic binding function
[Eq. (2)] with a single binding site. The dissociation
constants for binding are calculated to be 6.5 6 0.2 lM
and 22 6 3 lM for native and latent PAI-1, respectively. In
Panel B, varying concentrations of magnesium chloride
were mixed with PAI-1 (2 lM) and then passed over
immobilized nickel on the NTA-chip.

conformational effects may differ between Type I
and Type II metals.35 The SPR binding screen
worked well, but only with nickel binding because
the NTA resin is designed for optimal binding to
nickel, whereas other metals have lower affinity for
the resin. Just as with the IMAC procedure,35 such
results must be interpreted with caution and cannot
be used to infer an intrinsic metal binding site. NTA
is tetradentate and provides four coordination sites
for Ni binding. Thus, Ni bound to NTA can coordinate with two additional functional groups (often
histidine ligands) within a protein to fulfill its six
coordination sites. Obviously, these conditions can be
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Figure 2. Approach-to-equilibrium changes in PAI-1 intrinsic protein fluorescence upon mixing with Type II metals. Panels A
and B show representative results in MOPS buffer, whereas Panels C and D give results from Tris buffer (see Materials and
Methods). PAI-1 was mixed 1:1 with NiCl2 (A), CoCl2 (B), NiCl2 (C), or CuCl2 (D). The free metal concentrations were
calculated from the total metal concentration and the buffer/metal affinity constant using known metal:MOPS affinities (see
Materials and Methods). Changes in intrinsic protein fluorescence emission at wavelengths above 320 nM were monitored
continuously for 500 s. After subtraction of background (see Materials and Methods), data with all metals gave good fits to a
triple exponential equation with acceptable residuals, shown in the bottom frame below each of the panels. The inset to Panel
D shows an expanded view of the data at the earliest time points to more easily visualize the rapid decrease in fluorescence
that occurs upon mixing with copper.

with CoCl2, NiCl2, or CuCl2 gave response curves
that showed an initial drop in the intrinsic fluorescence of PAI-1, followed by an increase [Fig. 2(A–
D)]. Because of known interactions between buffers
and metal, we designed these experiments to be performed in buffers for which binding affinities have
been explicitly determined and for which these
interactions can be minimized.38–41 Stopped-flow
measurements of changes in PAI-1 fluorescence in
MOPS buffer are shown in Figure 2(A,B) for nickel

Thompson et al.

and cobalt binding to PAI-1. Copper solubility in
MOPS was problematic, so experiments with copper
were pursued with Tris buffer, as shown in Figure
2(D). As a control for comparing results in the two
buffers, we also measured approach-to-equilibrium
binding of nickel to PAI-1 in Tris buffer, as shown in
Figure 2(C). As can be seen by comparing Figure
2(A) with Figure 2(C), the changes that occur in the
fluorescence of PAI-1 under these presteady-state
conditions in the two buffers with nickel are
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Figure 3. The rate constant, kobs,1, resulting from the approach-to-equilibrium binding studies of Type II metals to PAI-1,
shows a hyperbolic dependence on metal concentration. PAI-1 was mixed 1:1 with increasing concentrations of nickel,
cobalt, or copper. For nickel and cobalt experiments, data were collected for 500 s and were fit to a triple exponential
equation after subtraction of background fluorescence changes, as described in the Materials and Methods section. For
copper, the time window was reduced to 50 s, and the data were fit to a double exponential equation after subtraction of
background (see Materials and Methods). Changes in the magnitude of kobs,1 versus free metal concentration were plotted for
nickel (A) and cobalt (B) in MOPS buffer as well as nickel (C) and copper (D) in Tris buffer. kobs,1 increased in a hyperbolic
fashion consistent with a two-step binding model in which there is an initial fast equilibrium binding step followed by a slower
conformational change (Scheme 1). Nonlinear least-squares fits to Eq. (1) are shown.

comparable. For all three metals in either buffer,
these changes in fluorescence were clearly multiphasic and fit well to three exponentials yielding the
observed rate constants kobs,1, kobs,2, and kobs,final,
respectively.
These stopped-flow experiments were performed
over a broad range in metal concentrations to distinguish between binding events, which are concentration dependent, and conformational changes, which
are not. When so evaluated using varied metal concentrations, it was determined that kobs,1 measured
upon Type II metal binding to PAI-1 increased in a
concentration-dependent manner (Fig. 3), whereas
kobs,2 and kobs,final did not. The increase in kobs,1
approached a limiting rate (Fig. 3), a result consistent with a two-step binding process as illustrated in
Scheme 1.42,43
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Scheme 1.

Kobs ¼ K2 þ ðk2  ½MÞ=ðKd þ ½MÞ

where Kd ¼ k1 =kl :
(1)

In this model, there is an initial rapid equilibrium
established between active PAI-1 (PA) and metal (M),
with forward and reverse rate constants (k1 and k1)
defining the binding affinity Kd, followed by a conformational change (*PAM) described by the rate
constants k2 and k2 characterizing the forward and
reverse conformational changes, respectively. The
data (Fig. 3) fit well to the equation [Eq. (1)]

Structure and Activity of Human PAI-1

Table I. Parameters from Fitting of kobs,1 versus
Ligand Concentration Using Nonlinear Least Squares
to Eq. (1) for Approach-to-Equilibrium Changes
in PAI-1 Intrinsic Protein Fluorescence
Metal

Buffer

k2 (s1)

Kd (lM)

Cobalt MOPS
34
Nickel MOPS
38
Nickel
Tris
32
Copper Tris 0.086

6
6
6
6

k2 (s1)

13
0.22 6 0.02 0.026
6
2.36 6 0.09 0.074
2
0.34 6 0.01 0.015
0.027 4.4 6 0.4 0.29

6
6
6
6

0.013
0.052
0.02
0.51

sponding to the decrease in fluorescence observed
with the Type II metals that directly reports binding
of the metals to PAI-1. Consistently, using a similar
time window, mixing with varying concentrations of
either of these metals resulted in no significant
changes in the observed rate constant for either
exponential, indicating that these changes are conformational events that occur after binding. Thus, in

Kd, k2, and k2 represent the dissociation constant for the
initial binding and forward and reverse rates for the subsequent conformational change that occurs in PAI-1 upon
metal binding, as shown in Scheme 1. Errors shown come
directly from the fit.

describing this process, yielding both the dissociation constant for metal binding (Kd) and kinetic
characterization of the conformational step (k2 and
k2) (Table I).
The similarity of the fluorescence changes
within the Type II group indicates that these metals
bind in a similar fashion and likely at the same site.
These results also demonstrate that the affinity for
copper is high, that is, 200-fold tighter than either
for nickel or cobalt (Table I). Finally, they illustrate
the importance of our approach to explicitly account
for buffer:metal interactions and calculate the free
metal concentration, validated by the similarity in
the dissociation constants for nickel measured in the
two buffers (Table I). As MOPS and Tris have quite
different affinities for nickel, the two buffers require
substantially different total metal concentrations to
arrive at similar free metal concentrations (Table
II); yet, both buffers gave a similar free metal concentration range over which kobs,1 approaches its
limiting rate (Fig. 3), resulting in similar Kd values
for PAI-1:nickel binding in the two cases.

The transient-state experiments
demonstrate differences between Type I
and II metal binding to PAI-1
Experiments with the Type I metals showed a much
different effect compared to that observed with
CoCl2, NiCl2, and CuCl2. Rapid mixing of MgCl2 or
MnCl2 with PAI-1 showed an increase in fluorescence that fits well to a double exponential equation
[Fig. 4(A,B)], but without the initial phase correTable II. Calculated Dissociation Constants for Metal/
Buffer Binding Interactions
Metal
Magnesium
Manganese
Cobalt
Nickel
Nickel
Copper
a

Buffer
MOPS
MOPS
MOPS
MOPS
Tris
Tris

b1a

Ka (M1)

Kd (lM)

3.51
3.54
3.41
3.45
2.74
4.05








309
288
389
355
1820
89.1

3.24
3.47
2.57
2.82
5.50
1.12

10
103
103
103
102
104

Values for b1 were taken from Refs. 36–38.
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3

Figure 4. Approach-to-equilibrium changes in PAI-1
intrinsic protein fluorescence upon mixing with Type I
metals. PAI-1 was mixed 1:1 with MgCl2 (A) or MnCl2 (B) in
Tris buffer. Changes in intrinsic protein fluorescence
emission at wavelengths above 320 nM were monitored
continuously for 500 s. After subtraction of background (see
Materials and Methods), the data were fit to a double
exponential equation with acceptable residuals, represented
in the bottom frame below each of the panels. The free
metal concentration was calculated from the total metal
concentration and the buffer/metal affinity constant (see
Materials and Methods).
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Table III. Comparison of kobs,final from Approach-to-Equilibrium Changes in PAI-1 Intrinsic Protein
Fluorescence with klat Measured from Kinetics Measuring the Half-Life of PAI-1 Using Similar
Conditions for Buffer, pH, and Temperature
Metal

Buffer

Total metal

Free metal

None
Cobalt
Nickel

MOPS
MOPS
MOPS

NA
20 mM
20 mM

NA
250 lM
230 lM

kobs

final

(s1)

klat (s1)

NA
3.09 (60.02)  104
2.17 (60.04)  103

8.42 (60.20)  105
3.42 (60.07)  104
1.89 (60.13)  103

The values for kobs final come directly from the multiple exponential fitting, whereas that for klat is the mean and standard
error for three replicate experiments.

contrast with what is observed with the Type II metals, the binding event for Type I metals is not
detected by perturbations in any of four tryptophan
residues (86, 139, 175, or 262), which are the main
contributors to PAI-1 fluorescence using this
method,44 so that the binding event is not reported
directly. Instead, it appears that changes in the
microenvironment of these residues are only
observed subsequent to binding and are associated
with conformational changes in PAI-1. These results,
which show that Type I metal effects on PAI-1 upon
binding are much different than observed with the
Type II metals, are consistent with their differing
effects on the rate of conversion of active PAI-1 to its
latent form.

The timescale for klat corresponds to that for
the final change in PAI-1 fluorescence
measured in the stopped-flow experiments
As mentioned, because kobs,2 and kobs,3 do not vary
significantly with Type II metal concentrations,
these events appear to represent additional downstream conformational events that occur after metal
binding. Although the conformational change associated with kobs,2 cannot be assigned at present to a
known conformational event, we anticipated that the
final exponential (i.e., kobs,3) was slow enough that it
might correspond to the conformational transition of
PAI-1 from the active to latent form. Thus, we determined whether this event occurs on a similar timescale as that for conversion of active PAI-1 to the
latent conformation. To compare the rates directly,
the t1/2 of PAI-1 was measured alone or in the presence of added metals in the MOPS buffer at 20 C
(Table III). For experiments that used MOPS buffer,
klat, for PAI-1 with added NiCl2 and CoCl2 matched
very well with kobs,final determined from the mathematical fit of the approach-to-equilibrium binding
data (Table III). It should be noted that accurate

determination of kobs,final for CoCl2 required the
approach-to-equilibrium experiments to be performed over a longer timescale, 2000 s, rather than
the 500 s that was used in Figure 2. This was necessary because the initial timescale captured only a
small segment of the final step, leaving it poorly
defined [Fig. 2(B)]. At these longer timescales, it was
determined that the final exponential actually corresponded to a decrease in fluorescence (data not
shown).
Thus, because of the similarity with all of the
Type II metals between experimental measurements
of klat and the final observed rate constant, kobs final,
in the approach-to-equilibrium measurements, we
assign this step to the latency transition. Combining
these results with the model in Scheme 1 gave an
overall mechanism, Scheme 2, in which the last step
is the conversion to latent PAI-1 (PL). This model
shows intervening steps between kobs,1 and kobs final/
klat, which at this point are unassigned and likely
represent other conformational events.

Kinetic measurements of PAI-1 stability with
mixtures of metals are consistent with a
high-affinity copper interaction and suggest that
Type I and II metals bind in the same location
Although our kinetic studies suggested that PAI-1 is
promiscuous in its ability to interact with metals,35
there is likely a preference for the binding of
one metal over another. Affinity measurements
from approach-to-equilibrium studies suggest much
tighter binding to copper than other metals. To confirm the high-affinity copper interaction and validate
the determined binding constants, PAI-1 stability
was evaluated using a mixture of NiCl2 and CuCl2
[Fig. 5(A)]. For each of these Type II transition
metals, a characteristic t1/2 for conversion of PAI-1
to the latent form is observed,35 so it was reasoned
that PAI-1 in the presence of a mixture of the two

Scheme 2.
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Figure 5. Kinetic measurements of PAI-1 half-life at 20 C in
the presence of mixtures of metals. Panel A is a semilog
plot showing a single rate associated with the loss of PAI-1
inhibitory activity in the presence of 73 lM free nickel and
0.24 lM free copper (Table IV) compared with the loss of
PAI-1 inhibitory activity in the presence of the each metal
alone at a similar metal concentration. Panel B shows a
similar fit for the rate of loss of PAI-1 activity with a mixture
of 400 lM free magnesium and 0.24 lM free copper
(Table IV) compared with PAI-1 plus either of the metals
fixed at the same metal concentration. All measurements
were performed at 20 C, and the kinetic data represent the
mean and standard error for three separate experiments.

metals should give an intermediate t1/2 if the two
metals bind to the same site on PAI-1. The experiment was designed such that the free metal concentration for each metal was more the twice the Kd;

the free concentration of nickel was chosen in a 300fold excess over the free concentration of copper to
achieve conditions where competition for metals for
the binding site(s) was feasible because of the 300fold differential between the measured dissociation
constants (Table IV). Thus, this experimental design
was anticipated to give a 50% occupancy for each
metal that was predicted to yield a t1/2 midway
between that for each metal. The mixture of 0.135
mM CuCl2 and 2 mM NiCl2 (0.24 and 73 lM free
metal, respectively) gave data that fit well to a
single exponential [Fig. 5(A)] and yielded a t1/2 intermediate between that for the individual metals
(Table IV), as predicted. This result confirms the affinity measurements determined with the stopped
flow and indicates that these metals likely bind in
the same site.
In the SPR experiments, it appeared that
magnesium perturbed nickel binding to PAI-1, but it
was unclear whether magnesium (i.e., Type I) and
nickel (i.e., Type II) bound to the same or separate
sites. Thus, the kinetic approach to measure stability was performed to test for competition in binding
between magnesium and the most tightly bound
Type II metal, copper. Because the affinity of PAI-1
for magnesium was unknown, a 1600-fold excess of
magnesium (Table IV) was added to readily detect
competition for copper binding. Concentrations of
0.5 mM MgCl2 and 0.135 mM CuCl2 (400 and 0.24
lM free metal, respectively) were mixed with PAI-1,
and the effect of the mixture of metals on the rate of
conversion from the active to latent form was measured. The data again fit well to a single exponential
with the resulting t1/2 virtually identical to that for
PAI-1 plus MgCl2 [Table IV and Fig. 5(B)]. This
result indicates that Type I and II metal vie for the
same site with MgCl2 present in excess over CuCl2,
as suggested by the SPR measurements.

Discussion
In this study, we have used equilibrium binding
approaches, steady-state kinetics, and stopped-flow
measurements to demonstrate that Type I and Type
II metals invoke different structural changes in the
protein upon binding. This observation is consistent
with our work in the companion article in this

Table IV. Effects on the Rate of Conversion of Active PAI-1 to the Latent Form in the Presence
of Mixtures of Type I and Type II Metals
Additive
MgCl2
NiCl2
CuCl2
CuCl2 and NiCl2
CuCl2 and MgCl2

Total metal
500 lM
2000 lM
135 lM
Above
Above

Free metal
400 lM
73 lM
0.24 lM
Above
Above

klat (s1)
1.23 (60.01)
20.5 (60.8)
2.39 (60.14)
7.67 (60.11)
1.22 (60.05)







t1/2 (h)
5

10
105
105
105
105

15.7
0.94
8.1
2.51
15.7

(60.1)
(60.03)
(60.5)
(60.04)
(60.7)

The values for klat and the associated t1/2 at 20 C were calculated from kinetic experiments that measure the rate of loss
over time of PAI-1 antiprotease activity using tPA (Fig. 5).
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series,35 which shows that Type I and Type II metals
have dramatically different effects on the stability of
PAI-1. The Type I metals used in this work, including magnesium and manganese, appear to have
modest effects on the structure and function of PAI1, with negligible effects on the stability of the protein measured by its t1/2. The effects of the Type II
metals, including cobalt and nickel, are in stark contrast, leading to marked destabilization of PAI-1 and
rapid conversion to the latent form.

Metals invoke a series of conformational
changes in PAI-1
Clearly, there are differences in structural effects on
PAI-1 induced by the two types of metals. These are
most readily apparent from the stopped-flow
approach-to-equilibrium measurement of changes in
intrinsic tryptophan fluorescence upon metal binding to PAI-1. In the case of the Type II metals that
have the most distinct effects on function of the serpin, there are three exponentials that characterize
association of PAI-1. The fastest rate is associated
with a decrease in fluorescence that approaches a
limiting rate in a concentration-dependent fashion;
thus, it corresponds to a metal binding event,
followed by a conformational change. In contrast,
interaction with Type I metals gives changes in PAI1 structure that are associated with two events
characterized by rates that do not vary with metal
concentration. Likewise, the slower events observed
in the transient kinetics with Type II metals are
reminiscent of these changes that occur with Type I
metals and are essentially concentration independent. These changes in fluorescence do not directly
report the initial binding event, but instead indicate
conformational effects that occur subsequent to binding. The slowest of these rates occurs on the same
timescale as the conversion of PAI-1 from the active
to latent form, so it is tentatively assigned to this
transition.
The mechanism by which serpins inhibit proteases occurs via a series of carefully executed conformational changes. Although variability in reactive
center loop orientation is the most obvious among
the growing database of crystal structures on PAI1,7,23,45–48 there are conformational changes that
occur throughout the molecule. According to descriptions of movements that influence serpin function,
which have resulted from a variety of investigations
using structural and kinetic methods, such regions
that have been dubbed as the ‘‘gate’’ region, the
‘‘hinge’’ region, the ‘‘shutter’’ region, and so
forth.13,49–51 PAI-1 is particularly susceptible to
adopting different conformational states as the
active form is metastable.52 As the thermodynamically more stable form of PAI-1 is the latent conformation,52 the active conformation is adopted by folding in a local kinetic ‘‘trap,’’ with several other
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conformations that can be accessed with relatively
little energetic cost en route to the global minimum
that is achieved by reactive center loop insertion.
RCL insertion can result either by forming the covalent serpin-protease acyl intermediate53,54 or the
latent inhibitor.7 After either Type I or II metals associate with PAI-1, a series of conformational events
occur that are detected by changes in the fluorescent
tryptophan probes that are distributed throughout
the molecule. Thus, metals perturb the metastable
fold of PAI-1 to affect the half-life of the inhibitor.
With reactive transition metals such as copper, oxidative damage to a protein may occur. Although this
cannot be explicitly ruled out with PAI-1, the similar
step-wise changes in tryptophan fluorescence from
short to longer timescales with the three transition
metals tested, which differ in oxidative capacity, are
more consistent with changes in conformation rather
than site-specific oxidation. Also, the enhancement
of the stability of the active form of PAI-1 in the
presence of these metals and vitronectin argues
against oxidative damage.35

Copper binds to PAI-1 with the highest affinity
Steady-state SPR measurements indicate that active
PAI-1 binds to nickel with a dissociation constant of
6 lM, whereas stopped-flow experiments give a
slightly weaker affinity with a Kd in the 25–40 lM
range (Table I). Similar experiments with cobalt result
in an affinity at the high end of that range. Copper
binds much tighter than either of these metals, with
an affinity of between 60 and 115 nM (Table I). Kinetic
experiments testing effects of mixtures of metal on
PAI-1 stability are consistent with this conclusion,
showing that copper dominates among metals in
affecting PAI-1 function, so that a 300-fold higher
concentration of free nickel is required to compete
effectively for copper binding. Experiments with magnesium/copper mixtures also indicate that a large
excess (1600-fold higher concentration) of free magnesium competes for binding at the same site. Thus,
these data indicate a single metal-binding site on PAI1 can bind both to Type I and Type II metals, either
using different geometries or providing different sidechain or backbone atoms to accommodate different
metals at the same site. These different binding modes
invoke different conformational changes in PAI-1, as
detected by the distinct changes in intrinsic fluorescence that are apparent from the stopped-flow measurements with the different classes of metals.
How do these dissociation constants compare
with metal concentrations in vivo? The bioavailable
pool of any metal includes the amount of free metal
within a certain cellular/extracellular location, the
amount bound to proteins within that location, the
affinity of those proteins for the metal, and the ability of the bound metal to be transferred to another
protein. Copper, likely the most studied of the Type
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II metals, provides a good example. Human plasma
contains only about 0.1 pM free copper because
almost all is bound to other proteins,55 whereas the
intracellular copper pool is 8 lM.55,56 Within the
brain, second only to the liver in copper abundance,57,58 the cerebrospinal fluid contains 0.5–
2.5 lM of the metal, whereas the concentration
within the synaptic cleft reaches up to 15 lM.56,59 In
addition, dissociation constants for copper in the
hypothalamus are 6–40 lM.59 These values in
tissues are clearly in the range that would be significant given the low micromolar affinities for metals
measured in this work.

What biological processes have potential
roles for copper in regulating PAI-1
structure and activity?
PAI-1 and vitronectin are both present in the circulation and in the brain, and the dissociation constants measured in this study indicate that copper
binding would occur at these physiological concentrations. For example, copper has been shown to
have a role in vascular leakage, platelet–endothelium interactions, and vascular smooth muscle cell
reactivity. Significantly, vitronectin and PAI-1 are
colocalized in the ECM and fibrin matrices60,61 in a
wide variety of these pathologies, where the proteins
regulate cell–matrix interactions, cell migration, and
tissue remodeling. For example, recent elegant studies using X-ray fluorescent microprobe analysis have
revealed some key findings relative to copper and
angiogenesis.62 This work has demonstrated that
the distribution of copper is under exquisite spatial
regulation.63 During angiogenesis, it is translocated
from the perinuclear areas of the cell toward the
tips of extending filopodia, where it is transported
across the cell membrane into the extracellular
space. In this work, the authors suggest that copper
activates an extracellular target that is inactivated
during copper chelation therapy. Also, our recently
published work has shown a role for the proteins as
regulators of the fibrinolytic cascade acting extracellularly to activate brain-derived neurotrophic
factor in the suprachiasmatic nucleus, required for
regulating circadian rhythms.64 The activity of the
biological clock is mediated in part by the N-methylD-aspartate receptor, which has been shown to efflux
copper upon activation.64 Additional work will be
required to further evaluate metal effects in these
various processes and determine how such effects
link to PAI-1 and its binding partner, vitronectin.

Materials and Methods
Materials
The two-chain form of tPA (tc-tPA) was purchased
from Molecular Innovations, Nova, MI. Spectrozyme
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tPA was purchased from American Diagnostics,
Stamford, CT. Protease inhibitor cocktail P8849,
Ultrapure MOPS, and NaCl were purchased from
Sigma Aldrich, St. Louis, MO. Biotechnology-grade
ChelexV resin was purchased from Bio-Rad Hercules, CA. All other reagents were of analytical grade
and used without further purification.
R

PAI-1 expression, purification, and activity
Unless noted, PAI-1 was expressed and purified as
described previously.35 For some experiments, it was
necessary to modify standard procedures to purify
PAI-1 free of any bound metals without using EDTA
as a chelator. In these cases, PAI-1 was purified
using the following modifications. Sigma protease inhibitor cocktail P8849 was used in place of P8465.
The dialysis after the SP Sepharose column contained 5 g/L of ChelexV resin. Fractions eluted from
the nickel Sepharose column were pooled, concentrated, and dialyzed against 50 mM MOPS and
300 mM NaCl (both ultrapure buffers), pH 6.5, containing 5 g/L ChelexV resin. The dialyzed protein
was concentrated to 1–3 mL and then loaded onto
the S-100 column. The column was washed with
50 mM MOPS and 300 mM NaCl (both ultrapure
buffers, which were treated with ChelexV resin at 5
g/L for additional purity), pH 6.5. Fractions were
pooled, concentrated, and dialyzed against the same
buffer. Dialyzed protein was filtered through a 0.22lm membrane and stored at 80 C. Active PAI-1
was converted to its latent conformation by dialysis
into 50 mM Tris and 200 mM NaCl, pH 7.4, at room
temperature, followed by incubation in the same
buffer at 37 C for 3 days. The inhibitory activity of
the PAI-1 preparation was tested by titration with
tPA as described previously.35 PAI-1 stability in the
presence of metals was monitored as described
previously.35
R

R

R

SPR measurement of PAI-1 binding to
immobilized metals
Experiments were performed at room temperature
on a Biacore 3000 SPR instrument. Protein and
metal were dissolved in 50 mM Tris and 200 mM
NaCl, pH 7.4. Metal was loaded onto a NTA chip by
injecting 7 lL of a 0.5 mM metal solution at a 10 lL/
min. After a brief wash with 50 lM EDTA to ensure
all unbound metal was flushed from the system,
varying concentrations of PAI-1 were loaded onto
the chip at 20 lL/min for 2 min, flowing over the
cell with bound metal and a reference cell for comparison with no metal bound. The binding reached
steady state during this time period, and the equilibrium dissociation constant (KD) was calculated
according to the method outlined by Rich and
Myszka.65 The sensorgram responses at equilibrium
were plotted against PAI-1 concentration and fit by
nonlinear least squares to the equation:
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R¼

Rmax

C
KD

1þ KCD

;

(2)

where R is the observed response, Rmax is the maximal response, C is the analyte concentration, and
KD is the equilibrium dissociation constant. Dissociation was then monitored for 3 min. Following each
PAI-1 injection, metal was stripped from the chip by
injecting 10 lL of a 350 mM EDTA solution. For
competition experiments, the concentration of PAI-1
that gave half-maximal binding to the nickel-loaded
NTA chip was fixed and mixed with varying concentrations of magnesium. The PAI-1 plus magnesium
solutions were then injected at a flow rate of 20 lL/
mL for 2 min. Competition of magnesium for binding
of PAI-1 to the solid-phase nickel bound to the chip
was measured by decrease in steady-state binding in
the experiment.

Calculation of free metal concentrations
from total metal levels using buffer/
metal affinity constants
PAI-1/metal measurements were made in either
MOPS or Tris buffer based on metal solubility and
availability of known metal/buffer binding constants.
Using known first sphere buffer/metal affinity values, b1,39–41 the dissociation constant for metal in
MOPS or Tris buffer was calculated using the equation: 10^b1 ¼ Ka ¼ 1/Kd (Table II). The free metal
concentration was then determined using the quadratic equation: Mf ¼ Mt  [(Mt þ Bt þ Kd)  ((Mt þ
Bt þ Kd)2  4BtMt)1/2]/2, where Mf is the free
metal concentration, Mt is the total metal concentration, Bt is the total buffer concentration, and Kd is
the buffer/metal dissociation constant.

Stopped-flow measurement of PAI-1
metal binding
Stock solutions of PAI-1 and metal chloride were
made in ultrapure 50 mM MOPS or Tris and 150
mM NaCl, pH 7.4 (at 20 C). Buffer was treated with
5 g/L ChelexV resin and passed through a 0.22-lm
filter before use. In an Applied Photophysics SX-20
stopped-flow spectrometer equilibrated to 20 C, the
PAI-1 stock was rapidly mixed 1:1 with dilutions of
the metal chloride stock. Samples were excited at
280 nM using a xenon lamp with one monochromator (slits set at 2 and 4 mm). Intrinsic protein fluorescence was monitored 90 to incident light using a
320 nM cutoff filter. Five to ten thousand data
points were collected over the selected time window
using oversampling. For long time-course experiments (500–2000 s), high concentrations of PAI-1
(100–200 nM) were used, and only three shots were
averaged for each experiment. For 50-s experiments
using 10 nM PAI-1, a 15-shot average was needed to
achieve acceptable signal to noise. A baseline,
R
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recorded on samples of PAI-1 mixed with buffer only,
was subtracted from all data on PAI-1 plus added
metal chloride.
For magnesium, manganese, cobalt, and nickel
in MOPS buffer, measurements were made over a
500-s timescale using 200 nM PAI-1, while varying
the metal from 1 to 250 lM concentrations of free
metal. For nickel in Tris buffer, measurements were
performed over a similar timescale, but using
100 nM PAI-1 and varying the metal from 0.4 to
280 lM concentrations of free metal. Initial experiments with copper in Tris buffer were performed in
a similar manner as those for nickel in the same
buffer; however, because of the rapid drop in fluorescence observed for the first exponential, observed
even at very low free copper concentrations, the
timescale and protein/metal concentrations for these
experiments were altered to maintain pseudo-firstorder conditions and perform measurements with
free copper concentrations that were below saturating conditions. The final conditions used to measure
the copper effect on the observed rate constant for
the first exponential were 10 nM PAI-1, with the
free copper concentration varied from 0.04 to
1 lM. Free concentrations of metals in the buffer
were calculated as described above.

PAI-1 stability assay
The rate of conversion of PAI-1 to the latent form
was determined as previously described9 with the
following alterations. A sample of 100 nM PAI-1 was
equilibrated in 50 mM Tris-HCl buffer, pH 7.4, containing 150 mM NaCl at 20 C. These conditions
were chosen to calculate rate constants for the conversion of PAI-1 to latent form in a comparable setting to that used for the stopped-flow measurements.
Metal chloride samples were added to final concentrations given in Table IV, with calculated free concentrations shown also. Over time, aliquots of PAI-1
with or without metal were mixed with tc-tPA at a
final concentration of 50 nM PAI-1 and 60 nM tPA.
The relative amount of active PAI-1 was determined
by its ability to inhibit functional tPA using 1 mM
Spectrozyme tPA as a substrate and monitoring the
release of p-nitroaniline by absorbance at 405 nM.
Relative PAI-1 activity was normalized and fit to a
single exponential to determine klat, the rate constant for conversion to the latent form. All data are
the average of three separate experiments.
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